SG11201404836QA - Long-acting coagulation factors and methods of producing same - Google Patents
Long-acting coagulation factors and methods of producing sameInfo
- Publication number
- SG11201404836QA SG11201404836QA SG11201404836QA SG11201404836QA SG11201404836QA SG 11201404836Q A SG11201404836Q A SG 11201404836QA SG 11201404836Q A SG11201404836Q A SG 11201404836QA SG 11201404836Q A SG11201404836Q A SG 11201404836QA SG 11201404836Q A SG11201404836Q A SG 11201404836QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- methods
- producing same
- polynucleotides
- english
- Prior art date
Links
- 102000015081 Blood Coagulation Factors Human genes 0.000 title abstract 3
- 108010039209 Blood Coagulation Factors Proteins 0.000 title abstract 3
- 239000003114 blood coagulation factor Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 101800005309 Carboxy-terminal peptide Proteins 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Glass Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/372,540 US8759292B2 (en) | 2006-02-03 | 2012-02-14 | Long-acting coagulation factors and methods of producing same |
| PCT/IL2013/050107 WO2013121416A1 (en) | 2012-02-14 | 2013-02-05 | Long-acting coagulation factors and methods of producing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201404836QA true SG11201404836QA (en) | 2014-12-30 |
Family
ID=48983616
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201404836QA SG11201404836QA (en) | 2012-02-14 | 2013-02-05 | Long-acting coagulation factors and methods of producing same |
Country Status (22)
| Country | Link |
|---|---|
| EP (3) | EP2822576B1 (xx) |
| JP (2) | JP6242819B2 (xx) |
| KR (3) | KR102310704B1 (xx) |
| CN (2) | CN104427994A (xx) |
| AU (3) | AU2013219935B2 (xx) |
| BR (1) | BR122021004014B1 (xx) |
| CA (1) | CA2870621C (xx) |
| CL (2) | CL2014002183A1 (xx) |
| CO (1) | CO7131365A2 (xx) |
| DK (2) | DK3326642T3 (xx) |
| EA (2) | EA028578B1 (xx) |
| ES (2) | ES2855133T3 (xx) |
| HK (1) | HK1205460A1 (xx) |
| HU (1) | HUE053068T2 (xx) |
| IL (2) | IL264959B (xx) |
| MX (3) | MX362446B (xx) |
| MY (1) | MY172539A (xx) |
| NO (1) | NO2920022T3 (xx) |
| PE (1) | PE20142290A1 (xx) |
| PL (1) | PL3326642T3 (xx) |
| SG (1) | SG11201404836QA (xx) |
| WO (1) | WO2013121416A1 (xx) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| EP2822576B1 (en) * | 2012-02-14 | 2018-01-10 | OPKO Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20180111974A1 (en) | 2014-12-10 | 2018-04-26 | Opko Biologics Ltd. | Methods of producing long acting ctp-modified growth hormone polypeptides |
| EP3310347B1 (en) * | 2015-06-19 | 2021-08-04 | OPKO Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| WO2017024060A1 (en) | 2015-08-03 | 2017-02-09 | Biogen Ma Inc. | Factor ix fusion proteins and methods of making and using same |
| TW201808988A (zh) * | 2016-07-11 | 2018-03-16 | 歐科生物製品有限公司 | 長效型凝血因子及其生產方法 |
| CN106279437B (zh) * | 2016-08-19 | 2017-10-31 | 安源医药科技（上海）有限公司 | 高糖基化人凝血因子viii融合蛋白及其制备方法与用途 |
| CN107759694B (zh) | 2016-08-19 | 2023-01-13 | 安源医药科技（上海）有限公司 | 双特异性抗体及其制备方法与用途 |
| WO2018032638A1 (zh) | 2016-08-19 | 2018-02-22 | 安源医药科技（上海）有限公司 | 用于构建融合蛋白的连接肽 |
| JP7023925B2 (ja) | 2017-03-08 | 2022-02-22 | テイ・エス テック株式会社 | 乗物用シート |
| US11981718B2 (en) | 2020-05-27 | 2024-05-14 | Ampsource Biopharma Shanghai Inc. | Dual-function protein for lipid and blood glucose regulation |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| DE3421468A1 (de) | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US6225449B1 (en) * | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
| DK0461200T3 (da) | 1989-02-21 | 1997-03-10 | Univ Washington | Modificerede former af reproduktionshormoner |
| US5792460A (en) * | 1989-02-21 | 1998-08-11 | Washington University | Modified glycoprotein hormones having a CTP at the amino terminus |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
| US7795210B2 (en) * | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
| CN1245510C (zh) * | 2003-09-25 | 2006-03-15 | 复旦大学 | 长效重组组织因子途径抑制物及其制备方法 |
| US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| US7553941B2 (en) * | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| US8048849B2 (en) * | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US8759292B2 (en) * | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
| TWI538916B (zh) * | 2008-04-11 | 2016-06-21 | 介控生化科技公司 | 經修飾的因子vii多肽和其用途 |
| US8865868B2 (en) * | 2008-08-06 | 2014-10-21 | Novo Nordisk Healthcare Ag | Conjugated proteins with prolonged in vivo efficacy |
| EP2822576B1 (en) | 2012-02-14 | 2018-01-10 | OPKO Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| EA033788B1 (ru) * | 2012-11-20 | 2019-11-26 | Opko Biologics Ltd | Способ увеличения гидродинамического объема полипептида путем присоединения карбоксиконцевого пептида гонадотропина |
-
2013
- 2013-02-05 EP EP13749077.7A patent/EP2822576B1/en active Active
- 2013-02-05 PL PL18150731T patent/PL3326642T3/pl unknown
- 2013-02-05 KR KR1020207015367A patent/KR102310704B1/ko active IP Right Grant
- 2013-02-05 BR BR122021004014-1A patent/BR122021004014B1/pt active IP Right Grant
- 2013-02-05 SG SG11201404836QA patent/SG11201404836QA/en unknown
- 2013-02-05 MX MX2014009910A patent/MX362446B/es active IP Right Grant
- 2013-02-05 PE PE2014001261A patent/PE20142290A1/es active IP Right Grant
- 2013-02-05 EA EA201491519A patent/EA028578B1/ru unknown
- 2013-02-05 CN CN201380019660.8A patent/CN104427994A/zh active Pending
- 2013-02-05 EP EP20204439.2A patent/EP3791890A1/en active Pending
- 2013-02-05 EA EA201790960A patent/EA201790960A3/ru unknown
- 2013-02-05 ES ES18150731T patent/ES2855133T3/es active Active
- 2013-02-05 EP EP18150731.0A patent/EP3326642B1/en active Active
- 2013-02-05 DK DK18150731.0T patent/DK3326642T3/da active
- 2013-02-05 JP JP2014557168A patent/JP6242819B2/ja active Active
- 2013-02-05 HU HUE18150731A patent/HUE053068T2/hu unknown
- 2013-02-05 KR KR1020217031683A patent/KR102630953B1/ko active IP Right Grant
- 2013-02-05 CN CN201811365443.5A patent/CN109535245A/zh active Pending
- 2013-02-05 ES ES13749077.7T patent/ES2665319T3/es active Active
- 2013-02-05 DK DK13749077.7T patent/DK2822576T3/en active
- 2013-02-05 MY MYPI2014002356A patent/MY172539A/en unknown
- 2013-02-05 KR KR1020147025500A patent/KR102118729B1/ko active IP Right Grant
- 2013-02-05 CA CA2870621A patent/CA2870621C/en active Active
- 2013-02-05 WO PCT/IL2013/050107 patent/WO2013121416A1/en active Application Filing
- 2013-02-05 AU AU2013219935A patent/AU2013219935B2/en active Active
- 2013-11-13 NO NO13855153A patent/NO2920022T3/no unknown
-
2014
- 2014-08-14 MX MX2022008807A patent/MX2022008807A/es unknown
- 2014-08-14 MX MX2019000708A patent/MX2019000708A/es unknown
- 2014-08-14 CO CO14178314A patent/CO7131365A2/es unknown
- 2014-08-14 CL CL2014002183A patent/CL2014002183A1/es unknown
-
2015
- 2015-06-25 HK HK15106044.6A patent/HK1205460A1/xx unknown
-
2016
- 2016-05-03 AU AU2016202829A patent/AU2016202829B2/en active Active
-
2017
- 2017-08-24 AU AU2017219044A patent/AU2017219044B2/en active Active
- 2017-09-04 CL CL2017002233A patent/CL2017002233A1/es unknown
- 2017-11-08 JP JP2017215861A patent/JP6510002B2/ja active Active
-
2019
- 2019-02-21 IL IL264959A patent/IL264959B/en unknown
-
2021
- 2021-04-07 IL IL282121A patent/IL282121B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
| SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201408054RA (en) | Pegylated oxm variants | |
| SG11201807912SA (en) | Vaccine against rsv | |
| SG11201408646VA (en) | Dimeric protein with triple mutations | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201907846VA (en) | Therapeutic rna | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201408261UA (en) | Syringe | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
| SG11202000312UA (en) | Encapsulated polynucleotides and methods of use | |
| SG11201907209QA (en) | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof | |
| SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201810687SA (en) | Serum albumin-binding fibronectin type iii domains | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer |